Selenium-Enriched Yeast Supplementation and Its Influence on Nerve Function Parameters and Oxidative Stress Markers in Diabetic Peripheral Neuropathy: A Randomized Placebo-Controlled Study.

Both selenium and placebo groups showed significant within-group reductions in neuropathy symptoms, but the between-group difference was not statistically significant.

• Neuropathy symptoms were assessed using the Michigan Neuropathy Screening Instrument (MNSI)
• Selenium group showed significant symptom reduction (p < 0.001); placebo group also showed significant reduction (p = 0.001)
• Intergroup difference was non-significant with adjusted mean difference (aMD) of -0.92 (95% CI: -1.9 to 0.10)
• Study used a modified intention-to-treat approach with ANCOVA adjusting for confounders

Neuropathy severity decreased significantly in the selenium group but not in the placebo group.

• Neuropathy severity was assessed using the Toronto Clinical Scoring System (TCSS)
• Selenium group showed significant reduction in severity (p = 0.002)
• Placebo group did not show a significant reduction in neuropathy severity
• Between-group significance was not explicitly reported as significant for this outcome

Pro-oxidant-antioxidant balance (PAB) levels declined markedly within the selenium group, but the between-group difference was not statistically significant.

• PAB levels were assessed via a specialized serum assay
• Within the selenium group, PAB declined significantly (p = 0.001)
• The between-group adjusted mean difference was -32.1 (95% CI: -66.02 to 1.87), which was non-significant
• The confidence interval just crossed zero, indicating a trend toward improvement that did not reach statistical significance

Sexual satisfaction improved significantly in the selenium group compared to the placebo group.

• Sexual satisfaction was assessed using the Larson Sexual Satisfaction Questionnaire (LSSQ)
• The adjusted mean difference between groups was 8.51 (95% CI: 0.74 to 16.28), which was statistically significant
• This was the only outcome with a statistically significant between-group difference favoring selenium
• Participants were aged 40–70 years with diagnosed diabetic peripheral neuropathy

The trial design involved 50 participants randomized 1:1 to receive 200 µg daily selenium-enriched yeast or placebo for 8 weeks.

• Selenium was derived from Saccharomyces cerevisiae yeast at a dose of 200 µg per day in a 500 mg capsule
• Study was triple-blind and placebo-controlled with randomization in a 1:1 ratio
• Duration of supplementation was 8 weeks
• Participants were adults aged 40–70 years with diabetic peripheral neuropathy
• Trial was registered at the Iranian Registry of Clinical Trials (IRCT20131009014957N10)